

Structural Characterisation of the *E. coli* Heat Stable Enterotoxin STh

Irena Matecko¹, Bjoern M. Burmann¹, Kristian Schweimer¹, Hubert Kalbacher², Jürgen Einsiedel³, Peter Gmeiner³ and Paul Rösch^{*,1}

¹University of Bayreuth, Department of Biopolymers & Research Center for Bio-Macromolecules, D-95440 Bayreuth, Germany

²PANATecs GmbH, Vor dem Kreuzberg 17, D-72070 Tübingen, Germany

³Department of Medicinal Chemistry, Friedrich-Alexander-University Erlangen - Nürnberg, Schuhstrasse 19, D-91052 Erlangen, Germany

Abstract: *E. coli* heat stable enterotoxin STa is an agonist of the membrane guanylate cyclase C whose endogenous ligands are the peptide hormones guanylin and uroguanylin. Whereas these peptides contain only two disulfide bonds, STa is stabilized by one additional disulfide bridge. We chemically synthesized the enterotoxin STh that originates from the *E. coli* strain found in humans, and we determined its structure and its dynamics by nuclear magnetic resonance spectroscopy and molecular dynamics calculations. Chemical synthesis clearly proved successful and resulted in the formation of the native disulfide bonds. The endogenous ligands guanylin and uroguanylin show the same general structural features and dynamics properties as the enterotoxin.

Keywords: Enterotoxin, guanylyl cyclase, STh, STa, guanylin, uroguanylin.

INTRODUCTION

Many bacterial pathogens synthesize toxins that serve as virulence factors. Recently, these toxins became a topic of interest as a medication [1-3], inactive toxin components (toxoids) were suggested to be used as a vaccine [4], toxins were used as tools to elucidate the complex events during signal transduction [5], even as tumor markers and potential therapeutics in the treatment of colorectal and breast cancer [6-8].

Enterotoxigenic *E. coli* bacteria (ETEC) produce two forms of heat-stable enterotoxins: STa (or STI) and STb (or STII) [9,10]. These toxins cause acute and secretory diarrhea in humans, known as traveler's disease. In developing countries, this type of diarrhea is a major cause of death of infants [11]. STa consists of two subtypes that differ slightly in amino acid sequence and that are, for historic reasons, called STh (originally thought to occur in human *E. coli* strains only) and STp (originally thought to occur in porcine *E. coli* strains only).

STh is expressed as a precursor protein of 72 amino acids and it is cleaved twice before it is secreted as the mature 19 amino acid toxin [12-15]. The toxic domain of STh is located in its carboxy-terminal region, between C6-C18, and it is highly conserved within the whole toxin family [5]. The 6 cysteins in this domain are arranged in three disulfide bridges, C6-C10, C7-C15 and C11-C18 [10] (Fig. 1) that are crucial for the peptide's toxicity [16,17]. The same disulfide pattern and, generally, high sequence similarity is observed

in guanylin and uroguanylin (Fig. 1), the endogenous peptide hormones that physiologically target the same receptor, membrane guanylate cyclase C, which is located at the brush border of the surface of cells of the intestine, and STh is able to displace both of these hormones from their receptor binding site [5,18-22].




Fig. (1). Comparison of the amino acid sequences and disulfide bridge patterns of the heat stable enterotoxin from the human strain of enterotoxigenic *E. coli* and human hormones guanylin and uroguanylin. Possible binding region of the peptides are marked gray.

The initial step for the biological effect of STa is its binding to the extracellular domain of GC-C. This interaction leads to over activation of the intracellular GC-C cGMP kinase, which, in turn, results in an excessive signal to the cystic fibrosis transmembrane conductance regulator on the apical plasma membrane of small intestinal enterocytes that, in turn, elicits extreme chloride and fluid secretion [5,20,23,24].

Although the interaction of STa with GC-C is of crucial importance to this process, little is known about its molecu-

*Address correspondence to this author at the University of Bayreuth, Department of Biopolymers & Research Center for Bio-Macromolecules, D-95440 Bayreuth, Germany; E-mail: roesch@unibt.de

lar basis, and only a crystal structure (PDB: 1ETN, [25]) and an NMR solution structure of STI are known [26]. We are currently examining the structural basis of STh recognition by GC-C, and, as an initial step, we determined the solution structure of the chemically synthesized STh(6-19).

ENTEROTOXIN SYNTHESIS AND REFOLDING

The synthesis of STh(6-19) was performed using the Fmoc/But and maximal temporary protection strategy on a Syro II peptide synthesizer (MultiSynTech, Witten, Germany). The chemical procedure used 0.05 mmol of Fmoc-Tyr(tBu)-2-chlorotriptyl resin, an eightfold excess of each amino acid (Fmoc Cys(Trt)-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Ala-OH), Fmoc-Pro-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu-OH and Fmoc-Glu(OtBu)-OH and 2-(1H-benzotriazole-1-yl)1,1,3,3-tetramethyluronium tetrafluoroborate/1-hydroxybenzotriazole (TBTU/HOBt) activation. Deprotection (2 h) and cleavage (100 mg peptide of resin) were achieved using 5 ml of a mixture of trifluoroacetic acid/thioanisole/ethanedithiole (90/8/2, vol/vol/vol). The acidic mixture was then precipitated three times with diethylether, dissolved in 10 % aqueous acetic acid and freeze dried. The crude toxin was purified by RP-HPLC on a C18 semi-preparative column (10 x 150 mm; Nucleosil) using a 40-min gradient of acetonitrile in 0.055% trifluoroacetic acid (10–80% B in 40 min, where B is 80 % acetonitrile/H₂O/0.05 % trifluoroacetic acid).

Oxidation of the reduced toxin was achieved by dissolving the purified peptide into 2 M acetic acid, and diluted to a peptide concentration of 0.015 mM in the presence of reduced/oxidized glutathione (molar ratio of peptide/GSH/GSSG was 1: 100: 10) and 2 M guanidine hydrochloride. The solution was adjusted to pH 8.0 with aqueous NH₄OH and stirred slowly at 4 °C for 7 d. The folding reaction was monitored by analytical HPLC. The solution was concentrated using a C18 SepPak (Waters) cartridge and finally lyophilized. Initial purification of the oxidized product was achieved by chromatography on a C8 column using the system above and yielding a purity of ~ 90 %. Finally, the product was highly purified on a C18 column using a 60-min gradient, resulting in a purity of 95 %. The quality of the product was confirmed by analytical HPLC, matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-MS) giving the correct mass in excellent agreement of the oxidized product. (M+H)_{calc} reduced: 1482.45; found: 1482.42; (M+H)_{calc} oxidized: 1476.41; found 1476.43.

NMR SPECTROSCOPY

Two-dimensional NMR spectra were recorded on Bruker DRX600 and AV800 spectrometers at 283 K with standard methods [27]. Standard ¹H-¹H correlated spectroscopy (COSY), ¹H-¹H total correlated spectroscopy (TOCSY) and ¹H-¹H homonuclear Overhauser enhancement spectroscopy (NOESY) were carried out with 4096x512 complex data points with excitation sculpting for water suppression [28] or coherence selection by pulsed field gradients [29]. Presaturation was applied for residual water suppression in experiments with the D₂O sample. ¹H-¹³C heteronuclear single quantum correlation (¹H-¹³C HSQC) and ¹H-¹³C-HMQC-TOCSY were used for ¹³C assignment and validation of the

¹H assignments. Peptide concentration was 3 mM, pH 3.0 in H₂O/D₂O (9: 1, v/v, 600μL) and in D₂O (99.98 %). For measurement in D₂O, STh was lyophilized repetitively from D₂O to exchange the amide protons and finally dissolved in D₂O, pH3. Spectra were processed and analyzed with in-house software and NMRView 5.2.2 [30].

STRUCTURE CALCULATIONS AND ANALYSIS

The total number of nontrivial unambiguous cross peaks in NOESY spectra was 190. The cross peaks were divided into three groups according to their relative intensities: strong with upper distance limit < 0.3 nm; medium, < 0.4 nm; and weak < 0.5 nm. Structure calculations were performed by using a modified *ab initio* SA protocol with the X-PLOR-NIH package [31]. The disulfide bonds were included explicitly. For each calculation 30 structures were calculated and 7 structures for each state were selected with the criteria for the lowest overall energy. Rasmol 2.7.3 [32,33] and PyMol [34] were used for molecular presentation. The geometry of the structures was analyzed using PROCHECK-NMR [35-37].

MD-SIMULATIONS

For further analysis and verification of our structural results we did an *ab initio* molecular dynamics simulation for STh and the hormones uroguanylin and guanylin [38]. The Amber 9 program package [39] and the *ff03* force-field [40,41] were used for the simulations of the three peptides. Each of them was constructed as an elongated peptide chain within the LEaP module of AMBER with the disulfide bonding as the only restraints.

The peptides were solvated in a TIP3P waterbox [42] with the dimensions of 80x60x40 Å, and for neutralization of the system sodium counterions were added. Calculations were performed at 286 K and an external pressure of 1 atm. At this conditions the systems were minimized and equilibrated using the program SANDER. Initially, the whole system was minimized for 1000 steps and the water molecules and the counterions were relaxed around the fixed solute with a 100-ps MD run. The systems were slowly heated stepwise to 286 K for equilibrating at each temperature. MD production runs of 2-ns duration were then performed for the systems. The MD data was analyzed by using the PTRAJ program. Root mean square deviation (r.m.s.d.) calculations of the heavy atoms were referenced to the NMR-structure of STh and the structures of the hormones deposited in the PDB (Guanylin: 1GUA, Uroguanylin; 1UYA), respectively.

RESULTS AND DISCUSSION

A detailed and well resolved solution structure of STh is needed for better understanding of processes that are involved into peptide recognition by its receptor. We thus chemically synthesized STh(6-19) and analyzed its NMR spectra. The chemical synthesis resulted in a peptide that was active in binding to the membrane proximal extracellular subdomain of human GCC with a nanomolar dissociation constant (Matecko *et al.*, unpublished).

The amide region of the proton NMR spectrum of STh showed the large dispersion of 2.5 ppm characteristic for a peptide with defined structure (Fig. 2). Using standard through-




Fig. (2). NOESY spectra of STh(6-19) in H₂O, pH 3.0 and 288K.

Table 1. ¹H and ¹³C Chemical Shifts and the Assignment of STh(6-19) in H₂O at pH 3.0.

	HN	HA1	HA2	CA	HB1	HB2	CB	HG1	HG2	CG1	HD1	HD2	CD
Glu8	9.84	4.33		59.30	2.15	2.15	26.70	2.64	2.43				
Leu9	7.41	4.66		53.73	1.84	1.58	41.88	1.49			0.94	0.87	22.79
Cys10	9.33			58.11	3.31	3.46	39.80						
Cys11	8.38	4.33		58.11	3.21	2.88	36.87						
Asn12	7.19	5.16		51.42	2.89	2.82	41.80						
Pro13		4.31		64.55	2.28	2.28	32.10	1.97			3.72	3.76	51.75
Ala14	8.45	4.31		52.62	1.37	1.37	18.49						
Cys15	7.69	4.53		55.53	3.18	3.11	37.91						
Thr16	8.60	4.07		63.92	4.08		69.33	1.29		21.92			
Gly17	9.02	4.05	3.75	45.86									
Cys18	7.58	4.63		56.68	2.92	2.92	39.26						
Tyr19	8.38	4.57		57.95	3.11	2.91							HE2/- 6.79

Chemical shifts for Cys6, Sys7 could not be determined due to flexibility of amino terminus.

bond and through-space 2D homonuclear and heteronuclear correlation experiments at natural abundance most of the resonances could be assigned (Table 1), and only the amide proton of C7 and the resonances of C6 were not identified in the spectra. The severely increased linewidth of amide protons as well as the beta protons of residues C10, C11, L9 likely reflects conformational dynamics on the intermediate chemical shift time scale (μ s-ms). The ¹³C chemical shifts of cysteines are very sensitive to the oxidation state of the sulfur atom [43]. The C β resonances of C10, C11, C15 and C18 are in the range between 36.9 - 39.8 ppm. This characteristic down field shift indicates the oxidized state of these cysteines. The chemical shift of C7 (33.9 ppm) is in the intermediate region between upfield shifted resonances of re-

duced cysteines and downfield shifted resonances of oxidized cysteines, the NOE cross peaks between C7-HA and C15-HB1,2 protons, however, clearly demonstrate the presence of the disulfide bond between these two residues. From this data it can be deduced that C6 must also be oxidized. Direct observation of the other two disulfide bonds by means of NOE cross peaks was not possible due to overlap with trivial intraresidual signals. The presence of the three disulfide bonds is also consistent with the observed molecular weight by mass spectroscopy (expected mass: 1475.46 Da, measured: 1475.43 Da). The NOESY cross peaks between P13 δ -protons and the α -proton of N12 show the trans conformation of the proline. Slow solvent exchange of amide protons of C11, N12, and C15 (Fig. 2) suggests these residues to be

involved in hydrogen bonds. During the iterative structure determination hydrogen bonds between N12 CO and C15 H^N; C18 H^N and C15 CO and C10 H^N and C7 CO were deduced.

For the structure calculation 190 experimentally derived distance restraints were obtained. Due to the observed line broadening by conformational exchange NOE peak intensities were classified very conservatively to include effects of dynamical averaging. The ten accepted structures out of ten calculated superimpose with a backbone r.m.s.d. of 0.89 Å and show only low violations of experimental and geometrical restraints (Table 2). A PROCHECK-NMR analysis of STh shows that 51 % of the residues of the accepted structures are found in the most favoured regions and an additional 49 % in the allowed regions of the Ramachandran plot (Table 2).

Table 2. Structural Statistics

NOE Statistics	
Total NOE number	190
Short range	21
Medium range	16
Long range	153
Deviation from Standard Geometry and Experimental Restraints	
Bonds	0.00095 ± 0.0002
Angles	0.169 ± 0.023
Distance restraints	0.0036 ± 0.0011
Ramachandran plot statistics ^a	51 % / 31 % / 18 % / 0 %

^a Ramachandran plot statistics are determined by PROCHECK-NMR and are determined as follow: residues in most favored region, in additional region, in generously allowed region, and in disallowed region.

The solution structure of STh(6-19) is composed of an α -helical turn at its N-terminus region and two β -turns, between C11-C15, C15-C18 stabilised by the three disulfide bridges as mentioned before (Fig. 3).

The unavailability of the coordinates of the solution conformation from Garipey *et al.* [26] renders direct comparison of the structures impossible. Superimposing the present STh structure with the crystal structure (pdb code 1ETN [25]), however, resulted in a backbone r.m.s.d. of 1.6 Å for residues C7-C18, mainly due to different orientation of the carboxy terminus. Restricting the fit to residues C7-G16 lowers the rmsd to 0.9 Å, demonstrating similar conformations in solution and in the crystal. The receptor binding region of STh and the endogenic GC-C peptide ligands uroguanylin and guanylin is found to be from N12 - A14 for STh [44] and Y9 - A11 for guanylin [45]. In fact, these regions are highly solvent exposed for guanylin, uroguanylin, STp, and STh (Fig. 4).




Fig. (3). (A) Overlay of 13 NMR derived structures of STh (6-19). (B) Presentation of disulfide bridges in STh (6-19).

Ab initio MD simulations with the NMR structures of guanylin, uroguanylin, and STh as starting structures show high flexibility of all three peptides in the loop regions (Fig.




Fig. (4). Comparison of structures of (A) STp (5-17), PDB: 1ETN; (B) Uroguanylin human, PDB: 1UYA; (C) Guanylin human, PDB: 1GNA and (D) our calculated STh (6-19) structure. Possible binding sites are shown as sticks.

5). The r.m.s.d. values of heavy atoms are in the same range for all three peptides, despite the additional disulfide bridge in STh. To evaluate the importance of the three disulfide bridges for the structure calculation of STh, we performed the identical calculations as we did for the NMR-structure determination, however, without taking into account the disulfide bridges. The energetically most favourable 15 structures were virtually the same as from the calculation containing both, the NOE restraints and the disulfide bridges. The largest difference in the structures was in the N-terminal loop and the carboxy-terminus of the peptide which both were observed to show higher flexibility.




Fig. (5). RMSD of the heavy atoms during the MD. Sth (6-19) referenced to the present structure (black); Uroguanylin referenced to PDB: 1UYA (light grey); Guanylin referenced to PDB: 1GNA (dark grey).

In addition to differences in structure and dynamics, STh may act as a toxin because it does not contain the chymotrypsin cleavage site found in guanylin, the endogenous peptide that predominantly acts in the large intestine, as opposed to uroguanylin [45]. Chymotrypsin is an enzyme of the intestinal tract, and it cleaves after aromatic amino acids such as Y9 of guanylin (Fig. 1). In fact, the Y9NA10P double mutant of guanylin causes diarrhoea in suckling mice at much lower concentrations than the native peptide does [45]. Thus, one reason for the only transient action of native guanylin in the large intestine could be its rapid loss of its structure by enzymatic digestion.

ACKNOWLEDGEMENT

Financial support by the Deutsche Forschungsgemeinschaft to PR (MA2317/5-2) is gratefully acknowledged.

REFERENCES

- [1] Carter SR, Seiff SR. Cosmetic botulinum toxin injections. *Int Ophthalmol Clin* 1997; 37: 69-79.
- [2] Levine SR. Thrombolytic therapy for stroke: the new paradigm. *Hosp Pract (Minneapolis)* 1997; 15; 32(11): 57-64, 69-73.
- [3] Maseri A, Andreotti F. Targeting new thrombolytic regimens at specific patient groups: implications for research and cost-containment. *Eur Heart J* 1997; 18(Suppl F): F28-35.
- [4] Schmitt CK, Meysick KC, O'Brien AD. Bacterial toxins: friends or foes? *Emerg Infect Dis* 1999; 5: 224-34.
- [5] Hasegawa M, Shimonishi Y. Recognition and signal transduction mechanism of *Escherichia coli* heat-stable enterotoxin and its receptor, guanylate cyclase C. *J Pept Res* 2005; 65: 261-71.
- [6] Giblin MF, Gali H, Sieckman GL, et al. *In vitro* and *in vivo* evaluation of ¹¹¹In-labeled *E. coli* heat-stable enterotoxin analogs for specific targeting of human breast cancers. *Breast Cancer Res Treat* 2006; 98: 7-15.
- [7] Giblin MF, Sieckman GL, Shelton TD, Hoffman TJ, Forte LR, Volkert WA. *In vitro* and *in vivo* evaluation of ¹⁷⁷Lu- and ⁹⁰Y-labeled *E. coli* heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers. *Nucl Med Biol* 2006; 33: 481-8.
- [8] Giblin MF, Sieckman GL, Watkinson LD, et al. Selective targeting of *E. coli* heat-stable enterotoxin analogs to human colon cancer cells. *Anticancer Res* 2006; 26: 3243-51.
- [9] Shimonishi Y, Hidaka Y, Koizumi M, et al. Mode of disulfide bond formation of a heat-stable enterotoxin (STh) produced by a human strain of enterotoxigenic *Escherichia coli*. *FEBS Lett* 1987; 215: 165-70.
- [10] Nair GB, Takeda Y. The heat-stable enterotoxins. *Microb Pathog* 1998; 24: 123-31.
- [11] Levine MM, Caplan ES, Waterman D, Cash RA, Hornick RB, Snyder MJ. Diarrhea caused by *Escherichia coli* that produce only heat-stable enterotoxin. *Infect Immun* 1977; 17: 78-82.
- [12] Moseley SL, Hardy JW, Hug MI, Echeverria P, Falkow S. Isolation and nucleotide sequence determination of a gene encoding a heat-stable enterotoxin of *Escherichia coli*. *Infect Immun* 1983; 39: 1167-74.
- [13] Lee CH, Moseley SL, Moon HW, Whipp SC, Gyles CL, So M. Characterization of the gene encoding heat-stable toxin II and preliminary molecular epidemiological studies of enterotoxigenic *Escherichia coli* heat-stable toxin II producers. *Infect Immun* 1983; 42: 264-8.
- [14] Rao MC. Toxins which activate guanylate cyclase: heat-stable enterotoxins. *Ciba Found Symp* 1985; 112: 74-93.
- [15] Lathe R, Hirth P, DeWilde M, Harford N, Lecocq JP. Cell-free synthesis of enterotoxin of *E. coli* from a cloned gene. *Nature* 1980; 284: 473-4.
- [16] Garipey J, Judd AK, Schoolnik GK. Importance of disulfide bridges in the structure and activity of *Escherichia coli* enterotoxin ST1b. *Proc Natl Acad Sci USA* 1987; 84: 8907-11.
- [17] Yoshimura S, Ikemura H, Watanabe H, et al. Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic *Escherichia coli*. *FEBS Lett* 1985; 181(1): 138-42.
- [18] Hirayama T, Wada A, Hidaka Y, Fujisawa J, Takeda Y, Shimonishi Y. Expression of a truncated guanylate cyclase (GC-C), a receptor for heat-stable enterotoxin of enterotoxigenic *Escherichia coli*, and its dimer formation in COS-7 cells. *Microb Pathog* 1993; 15: 283-91.
- [19] Waldman SA, Kuno T, Kamisaki Y, et al. Intestinal receptor for heat-stable enterotoxin of *Escherichia coli* is tightly coupled to a novel form of particulate guanylate cyclase. *Infect Immun* 1986; 51: 320-6.
- [20] Hasegawa M, Hidaka Y, Matsumoto Y, Sanni T, Shimonishi Y. Determination of the binding site on the extracellular domain of guanylyl cyclase C to heat-stable enterotoxin. *J Biol Chem* 1999; 274: 31713-8.
- [21] Wada A, Hirayama T, Kitaura H, et al. Identification of ligand recognition sites in heat-stable enterotoxin receptor, membrane-associated guanylyl cyclase C by site-directed mutational analysis. *Infect Immun* 1996; 64: 5144-50.
- [22] Hasegawa M, Matsumoto-Ishikawa Y, Hijikata A, Hidaka Y, Go M, Shimonishi Y. Disulfide linkages and a three-dimensional structure model of the extracellular ligand-binding domain of guanylyl cyclase C. *Protein J* 2005; 24(5): 315-25.
- [23] Gardner P, Chao AC, De Sauvage F. STa receptors: Physiological and pathophysiological regulation of intestinal secretion by 5'-cyclic guanosine monophosphate. *Gastroenterology* 1995; 109(1): 325-7.
- [24] Harteneck C, Koesling D, Soling A, Schultz G, Bohme E. Expression of soluble guanylyl cyclase. Catalytic activity requires two enzyme subunits. *FEBS Lett* 1990; 272: 221-3.
- [25] Ozaki H, Sato T, Kubota H, Hata Y, Katsube Y, Shimonishi Y. Molecular structure of the toxin domain of heat-stable enterotoxin produced by a pathogenic strain of *Escherichia coli*. A putative binding site for a binding protein on rat intestinal epithelial cell membranes. *J Biol Chem* 1991; 266: 5934-41.

- [26] Garipey J, Lane A, Frayman F, *et al.* Structure of the toxic domain of the *Escherichia coli* heat-stable enterotoxin ST I. *Biochemistry* 1986; 25: 7854-66.
- [27] Cavanagh J, Fairbrother WJ, Palmer III AG, Skelton NJ. *Protein NMR Spectroscopy: Principles and Practice*. San Diego, CA: Academic Press; 2006.
- [28] Hwang TL, Shaka AJ. Water suppression that works. Excitation sculpting using arbitrary wave forms and pulsed gradients. *J Magn Res* 1995; 112A: 275-9.
- [29] Mori S, Abeygunawardana C, Johnson MO, van Zijl PC. Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation. *J Magn Res B* 1995; 108: 94-8.
- [30] Johnson BA. Using NMRView to visualize and analyze the NMR spectra of macromolecules. *Methods Mol Biol* 2004; 278: 313-52.
- [31] Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM. The Xplor-NIH NMR molecular structure determination package. *J Magn Res* 2003; 160: 66-74.
- [32] Bernstein HJ. Recent changes to RasMol, recombining the variants. *Trends Biochem Sci* 2000; 25: 453-5.
- [33] Sayle R, Milner-White EJ. RASMOL: Biomolecular graphics for all. *Trends Biochem Sci* 1995; 20: 374-6.
- [34] DeLano WL. *The PyMOL Molecular Graphics System*. DeLano Scientific, Palo Alto, CA, USA. 2002.
- [35] Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. *Proteins* 1992; 12: 345-64.
- [36] Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: A program to check the stereochemical quality of protein structures. *J Appl Cryst* 1993; 26: 283-91.
- [37] Laskowski RA, Rullmann JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. *J Biomol NMR* 1996; 8: 477-86.
- [38] Simmerling C, Strockbine B, Roitberg AE. All-Atom Structure Prediction and Folding Simulations of a Stable Protein. *J Am Chem Soc* 2002; 38: 11258-9.
- [39] Case DA, Darden TA, Cheatham TE, *et al.* AMBER 9, University of California, San Francisco, 2006.
- [40] Duan Y, Wu C, Chowdhury S, *et al.* A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. *J Comput Chem* 2003; 24: 1999-2012.
- [41] Lee MC, Duan Y. Distinguish protein decoys by using a scoring function based on a new AMBER force field, short molecular dynamics simulations, and the generalized born solvent model. *Proteins: Struct Funct Bioinf* 2004; 55: 620-34.
- [42] Price DJ, Brooks III CL. A modified TIP3P water potential for simulation with Ewald summation. *J Chem Phys* 2004; 121: 10096-103.
- [43] Sharma D, Rajarathnam K. ¹³C NMR chemical shifts can predict disulfide bond formation. *J Biomol NMR* 2000; 18: 165-7.
- [44] Carpick BW, Garipey J. Structural characterization of functionally important regions of the *Escherichia coli* heat-stable enterotoxin STIb. *Biochemistry* 1991; 30: 4803-9.
- [45] Carpick BW, Garipey J. The *Escherichia coli* heat-stable enterotoxin is a long-lived superagonist of guanylin. *Infect Immun* 1993; 61: 4710-5.

Received: August 15, 2008

Revised: October 27, 2008

Accepted: November 7, 2008

© Matecko *et al.*; Licensee Bentham OpenThis is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.